CN100497333C - 用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物 - Google Patents

用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物 Download PDF

Info

Publication number
CN100497333C
CN100497333C CNB038065452A CN03806545A CN100497333C CN 100497333 C CN100497333 C CN 100497333C CN B038065452 A CNB038065452 A CN B038065452A CN 03806545 A CN03806545 A CN 03806545A CN 100497333 C CN100497333 C CN 100497333C
Authority
CN
China
Prior art keywords
phenyl
pyridin
methyl
trifluoromethyl
dihydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038065452A
Other languages
English (en)
Chinese (zh)
Other versions
CN1633430A (zh
Inventor
G·亚当
E·格斯奇
J·维希曼
T·J·沃特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1633430A publication Critical patent/CN1633430A/zh
Application granted granted Critical
Publication of CN100497333C publication Critical patent/CN100497333C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB038065452A 2002-02-06 2003-01-28 用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物 Expired - Fee Related CN100497333C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06
EP02002012.9 2002-02-06

Publications (2)

Publication Number Publication Date
CN1633430A CN1633430A (zh) 2005-06-29
CN100497333C true CN100497333C (zh) 2009-06-10

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038065452A Expired - Fee Related CN100497333C (zh) 2002-02-06 2003-01-28 用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物

Country Status (30)

Country Link
US (1) US6949542B2 (https=)
EP (1) EP1474416B1 (https=)
JP (1) JP4077411B2 (https=)
KR (1) KR20040081486A (https=)
CN (1) CN100497333C (https=)
AR (1) AR038481A1 (https=)
AT (1) ATE374196T1 (https=)
AU (1) AU2003205695B8 (https=)
BR (1) BR0307474A (https=)
CA (1) CA2474219C (https=)
DE (1) DE60316538T2 (https=)
DK (1) DK1474416T3 (https=)
ES (1) ES2294264T3 (https=)
GT (1) GT200300028A (https=)
HR (1) HRP20040678A2 (https=)
IL (1) IL163102A (https=)
MX (1) MXPA04007516A (https=)
MY (1) MY176608A (https=)
NO (1) NO327697B1 (https=)
NZ (1) NZ534122A (https=)
PA (1) PA8565901A1 (https=)
PE (1) PE20031011A1 (https=)
PL (1) PL372425A1 (https=)
PT (1) PT1474416E (https=)
RU (1) RU2315764C2 (https=)
SI (1) SI1474416T1 (https=)
TW (1) TWI326599B (https=)
UY (1) UY27654A1 (https=)
WO (1) WO2003066623A1 (https=)
ZA (1) ZA200406032B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386980C (en) * 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders
AU2004262897B9 (en) * 2003-07-25 2009-12-17 F. Hoffmann-La Roche Ag Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
BRPI0810655A2 (pt) * 2007-04-19 2014-11-04 Hoffmann La Roche Derivados de di-hidro-benzo[b][1,4] diazepin-2-ona sulfonamida
EP2188263B1 (en) 2007-08-27 2012-06-27 F. Hoffmann-La Roche AG Benzimidazole derivatives used as fxr agonists
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
JP5693452B2 (ja) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BR112012003871A2 (pt) 2009-08-21 2015-09-08 Otsuka Pharma Co Ltd processo para a produção de composto de benzo[b][1,4]diazepina-2,4-diona
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
MX2012008346A (es) 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
MX2014002459A (es) 2011-08-30 2014-04-10 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
EP2925292A1 (en) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of autistic disorders
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
CA2950952C (en) * 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN106715421A (zh) 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン化合物（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＣＯＭＰＯＵＮＤ）
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105839T1 (de) * 1989-03-23 1994-06-15 Pfizer Antiallergische mittel auf der basis von diazepin.
CA2386980C (en) 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders
AU774451B2 (en) 1999-10-15 2004-06-24 F. Hoffmann-La Roche Ag Benzodiazepine derivatives

Also Published As

Publication number Publication date
JP2005522440A (ja) 2005-07-28
EP1474416B1 (en) 2007-09-26
BR0307474A (pt) 2004-11-09
PL372425A1 (en) 2005-07-25
WO2003066623A1 (en) 2003-08-14
PE20031011A1 (es) 2003-11-29
MXPA04007516A (es) 2004-11-10
IL163102A (en) 2011-07-31
EP1474416A1 (en) 2004-11-10
US6949542B2 (en) 2005-09-27
MY176608A (en) 2020-08-18
AR038481A1 (es) 2005-01-19
DE60316538T2 (de) 2008-08-21
DE60316538D1 (de) 2007-11-08
ZA200406032B (en) 2005-10-12
GT200300028A (es) 2004-06-11
ES2294264T3 (es) 2008-04-01
NO327697B1 (no) 2009-09-14
SI1474416T1 (sl) 2008-02-29
TWI326599B (en) 2010-07-01
US20030166639A1 (en) 2003-09-04
CA2474219C (en) 2010-04-13
DK1474416T3 (da) 2008-01-14
ATE374196T1 (de) 2007-10-15
NZ534122A (en) 2006-12-22
HRP20040678A2 (en) 2005-10-31
RU2004126945A (ru) 2005-06-27
PT1474416E (pt) 2007-12-27
TW200302730A (en) 2003-08-16
AU2003205695A1 (en) 2003-09-02
JP4077411B2 (ja) 2008-04-16
PA8565901A1 (es) 2003-09-05
RU2315764C2 (ru) 2008-01-27
KR20040081486A (ko) 2004-09-21
NO20043237L (no) 2004-08-02
CA2474219A1 (en) 2003-08-14
AU2003205695B2 (en) 2008-04-03
UY27654A1 (es) 2003-08-29
HK1078858A1 (zh) 2006-03-24
CN1633430A (zh) 2005-06-29
AU2003205695B8 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
CN100497333C (zh) 用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物
CN106061480B (zh) 治疗性抑制性化合物
CN108884068B (zh) 作为dub抑制剂的1-氰基-吡咯烷衍生物
CN100408564C (zh) 治疗hiv的吡唑衍生物
CN104302634B (zh) 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
CN103842340B (zh) 核转运调节剂及其应用
US12233065B2 (en) Inhibitors of RNA helicase DHX9 and uses thereof
CN103459382B (zh) 用于抑制pask的杂环化合物
CN102224142B (zh) 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物
CN102892759A (zh) 具有犬尿氨酸产生抑制作用的含氮杂环化合物
CN105143185A (zh) 新的嘧啶和吡啶化合物以及它们的用途
CN101641346A (zh) 作为mglur2拮抗剂的吡啶和嘧啶衍生物
JP2017500333A (ja) グルコース輸送阻害剤
WO2005023782A1 (ja) 置換された縮環ピリミジン－４（３ｈ）－オン化合物
WO2021213476A1 (zh) 一种吡唑并[1,5-a]吡啶类衍生物及其制备方法，组合物以及用途
HK1078858B (en) Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders
CN117430589A (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途
HK1230502B (zh) 治疗性抑制性化合物
HK1230502A1 (en) Therapeutic inhibitory compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078858

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1078858

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090610

Termination date: 20190128